title: Response to the letter to the editor entitled "Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization".
authors.affiliation: Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 1, 53100, Siena, Italy. gmtosi@tin.it.
authors.forename: Gian Marco
authors.initials: GM
authors.lastname: Tosi
authors.affiliation: Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 1, 53100, Siena, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Traversi
authors.affiliation: Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 1, 53100, Siena, Italy.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Nuti
authors.affiliation: Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 1, 53100, Siena, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Marigliani
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D047728:Myopia, Degenerative / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab